Florida, March 07, 2018:

    Cancer Diagnostics Market 2018 to 2022

    The worldwide cutting edge disease diagnostics business sector is divided on the premise of finding by growth sign, by diagnostics capacity and by sort of investigation. Cutting edge growth finding business sector is partitioned into bosom, colorectal and proteomic disease. Colorectal tumor portion is relied upon to develop at a huge rate because of expanding frequencies of colorectal growth in the worldwide populace and expanding research concentrates on in the biotechnology business.

    According to this report, the global cancer diagnostics market is expected to grow at a CAGR of more than 7% during the forecast period of 2015 to 2022. In 2014, the global cancer diagnostics market was valued at US$ 100 billion and is expected to be worth US$ 168 billion by 2022.

    Tumor is a hereditary malady driven by substantial or heritable transformations. Advancement of new DNA sequencing and cutting edge sequencing innovations are relied upon to have a huge effect in the treatment, administration and discovery of growth. Cutting edge disease diagnostics business sector is relied upon to witness a lucrative development amid the gauge period attributable to expanding applications as a consequence of mechanical headways in cutting edge tumor diagnostics, for example, improvement of computerized and new imaging modalities so as to break down X-beam mammograms.

    Browse the full report here: https://www.marketresearchengine.com/reportdetails/cancer-diagnostics-market

    The land investigation of cutting edge disease diagnostics market isolates it into North America, Europe, Asia-Pacific, Latin America and MEA. In 2015, North America represented the biggest piece of the overall industry in 2015 attributable to expanding use of cutting edge growth diagnostics systems in disease research, expanding appropriation of ease and reduced NGS tumor diagnostics measures in clinical diagnostics and research labs, and expanding nature of base for lab and clinical exploration. Developing economies, for example, China and India in the Asia Pacific locale are required to develop at a noteworthy rate all through the figure period. This normal development is credited for by expanding interest for financially savvy and safe malignancy medications in the locale , expanding government and corporate interest in the biotechnology and biopharmaceutical segment, rising per capita salary of the populace, expanding improvement and generation of new biologics, genomic measures, and sedates, growing restorative treatment for tumor analysis, expanding middle age of the populace and expanding concentrate on pulling in worldwide and residential players in the business sector.

    Cancer Diagnostics Market, by Method:

    • Biopsy
    • Endoscopy
    • Tumor Biomarker Tests
    • Imaging

    Major geographies analyzed under this research report are: 

    • Europe
    • North America
    • Asia-Pacific
    • Rest of the World

    This report gives you access to decisive data such as:

    • Market growth drivers
    • Factors limiting market growth
    • Current market trends
    • Market structure
    • Market projections for the coming years

    Buy Report from here: https://www.marketresearchengine.com/reportdetails/cancer-diagnostics-market

    Table of Contents

    1 INTRODUCTION    
    1.1    KEY TAKE AWAYS
    1.2    REPORT DESCRIPTION
    1.3    MARKETS COVERED
    1.4    STAKEHOLDERS
    1.5    RESEARCH METHODOLOGY
    1.5.1    MARKET SIZE
    1.5.2    MARKET SHARE
    1.5.3    KEY DATA POINTS FROM SECONDARY SOURCES
    1.5.4    KEY DATA POINTS FROM PRIMARY SOURCES

    2 Research Methodology
    2.1.1 Research Methodology Steps
    2.1.2 Secondary and Primary Research Methodology
    2.1.2.1 Secondary Research
    2.1.2.2 Key Data From Secondary Sources
    2.1.2.3 Primary Research
    2.1.2.4 Key Industry Insights
    2.1.5 Key Data From Primary Sources
    2.1.6 Key Insights From Primary Sources
    2.1.7 Market Size Estimation Methodology
    2.1.8 Market Forecast Methodology
    2.1.9 Market Data Validation and Triangulation
    2.1.10 Assumptions for the Study

    3 Executive Summary
    3.1 Introduction
    3.2 Current Scenario
    3.3 Future Outlook
    3.4 Conclusion

    4 Premium Insights
    4.1 Global Cancer Diagnostics Market
    4.2 Regional Snapshot of the Cancer Diagnostics Market
    4.3 Cancer Diagnostics Market, By Technology (2015 vs. 2020)

    5 Market Overview
    5.1 Key Findings
    5.2 Introduction
    5.3 Market Dynamics
    5.3.1 Drivers
    5.3.1.1 Rising Prevalence of Cancer
    5.3.1.2 Technological Advancements
    5.3.1.3 Initiatives Undertaken By Governments and Global Health Organizations to Spread Awareness About Cancer
    5.3.1.4 Growth in the Number of Private Diagnostic Centers
    5.3.1.5 Public-Private Partnerships to Enhance the Infrastructure of Diagnostic Imaging Centers
    5.3.1.6 Fda Support for Biomarker Development
    5.3.1.7 Launch of New Flow Cytometry Reagents for Diagnostics and Drug Discovery
    5.3.2 Restraints
    5.3.2.1 High Capital Investments & Low Benefit-Cost Ratio for Biomarkers
    5.3.2.2 Shortage of Helium
    5.3.2.3 High Cost of Diagnostic Imaging Systems Affecting Their Rate of Adoption in Emerging Markets
    5.3.2.4 Risk of High Radiation Exposure Likely to Limit the Usage of CT Scanners
    5.3.2.5 Dearth of Skilled and Experienced Personnel
    5.3.3 Opportunities
    5.3.3.1 Personalized Medicine
    5.3.3.2 Development of Mass Cytometry and the Combination of Cell-And Bead-Based Flow Cytometry Technologies
    5.3.3.3 Companion Diagnostics
    5.3.3.4 Improving Healthcare Infrastructure in Emerging Markets
    5.3.3.5 Miniaturized and Technologically Advanced Devices
    5.3.4 Challenges
    5.3.4.1 Stringent Regulatory Guidelines
    5.3.4.2 Hospital Budget Cuts A Key Challenge to Market Players
    5.3.4.3 Increasing Adoption of Refurbished Diagnostic Imaging Systems

    6 Global Cancer Diagnostics Market, By Technology
    6.1 Introduction
    6.2 Platform-Based Diagnostics
    6.2.1 Polymerase Chain Reaction (PCR)
    6.2.2 in Situ Hybridization (ISH)
    6.2.3 Immunohistochemistry (IHC)
    6.2.4 Next-Generation Sequencing (NGS)
    6.2.5 Microarrays
    6.2.6 Flow Cytometry
    6.2.7 Other Technologies
    6.3 Instrument-Based
    6.3.1 Diagnostic Imaging
    6.3.1.1 Magnetic Resonance Imaging (MRI)
    6.3.1.2 Computed Tomography (Ct)
    6.3.1.3 Positron Emission Tomography (PET)
    6.3.1.3.1 Standalone Positron Emission Tomography
    6.3.1.3.2 Hybrid Positron Emission Tomography
    6.3.1.4 Mammography
    6.3.1.5 Ultrasound
    6.3.2 Biopsies

    7 Global Cancer Diagnostics Market, By Application
    7.1 Introduction
    7.1.1 Breast Cancer
    7.1.2 Lung Cancer
    7.1.3 Colorectal Cancer
    7.1.4 Melanoma
    7.1.5 Other Cancers

    8 Market, By End User

    9 Cancer Diagnostics Market, By Region
    9.1 Introduction
    9.2 North America
    9.2.1 U.S.
    9.2.1.1 Government Initiatives
    9.2.1.2 Increase in Cancer Incidence
    9.2.2 Canada
    9.2.2.1 High Incidence of Cancer
    9.2.2.2 Government Funding
    9.3 Europe
    9.3.1 Funding for Cancer Diagnostics Research
    9.3.2 Eu-5 (U.K., Germany, France, Italy, Spain)
    9.3.2.1 Strong Government Support
    9.3.2.2 Research Collaborations
    9.3.2.3 Increase in Diagnostic Imaging Centers
    9.3.2.4 Rising Public and Private Investments
    9.3.3 Rest of Europe (RoE)
    9.3.3.1 Aging Population
    9.3.3.2 Conferences Boosting Awareness
    9.3.3.3 Government Investments in Russia
    9.4 Asia
    9.4.1.1 China
    9.4.1.1.1 Expansion of International Players
    9.4.1.1.2 Aging Population and Increasing Cancer Incidence
    9.4.1.2 Japan
    9.4.1.2.1 Aging Population and High Healthcare Expenditure in Japan
    9.4.1.3 India
    9.4.1.3.1 Increasing Focus of International Players on India
    9.4.1.4 Rest of Asia
    9.4.1.4.1 Presence of International Players Boosting Market Growth
    9.5 Rest of the World (RoW)
    9.5.1.1 Government Initiatives Boosting Demand for Cancer Diagnostics
    9.5.1.2 Aging Population, Presence of International Players
    9.5.1.3 Increase in Cancer Incidences and Rising Government Expenditure
    9.5.1.4 Government Initiatives to Improve Healthcare Infrastructure

    10 Competitive Landscape
    10.1 Overview
    10.2 Market Share Analysis
    10.3 Competitive Situation and Trends
    10.3.1 Collaborations/Agreements/Partnerships/Alliances
    10.3.2 New Product Launches
    10.3.3 Acquisitions
    10.3.4 Expansion
    10.3.5 Others

    11 Company Profiles

    11.1 Introduction

    11.2 Becton, Dickinson and Company

    11.3 GE Healthcare (A Subsidiary of General Electric Company)

    11.4 Abbott

    11.5 Roche

    11.6 Thermo Fisher Scientific, Inc.

    11.7 Agilent Technologies, Inc.

    11.8 Illumina, Inc.

    11.9 Siemens Healthcare

    11.10 C.R. Bard, Inc.

    Media Contact
    Company Name:
    Market Research Engine
    Contact Person: John Bay
    Email: john@marketresearchengine.com
    Phone: +1-855-984-1862
    Website: https://www.marketresearchengine.com/

     

    Source: http://www.financeswire.com/cancer-diagnostics-market-share-2018-industry-analysis-growth-and-forecast-to-2022